Table 6.
Prediction of LTRA therapy.
| Univariate Regression Analysis | Multivariate Regression Analysis | |||||
|---|---|---|---|---|---|---|
| ODD | IC 95% | p Value | ODD | IC 95% | p Value | |
| Age, y | 1.008 | 0.949–1.072 | 0.787 | 1.049 | 0.947–1.163 | 0.360 |
| Sex, female sex | 1.257 | 0.333–4.742 | 0.735 | 0.484 | 0.034–4.994 | 0.484 |
| BMI, kg/m2 | 1.176 | 0.957–1.445 | 0.123 | 0.136 | 0.909–2.008 | 1.351 |
| FeNO 50 T1, ppb | 0.97 | 0.93–0.99 | 0.024 | 0.955 | 0.919–0.993 | 0.021 |
| Unplanned visits to specialists T1/6 months | 0.331 | 0.144–0.761 | 0.009 | 0.179 | 0.048–0.673 | 0.011 |
Probability of LTRA therapy. ACT: asthma control test. ΔACT = ACT T1 − ACT T0. FeNO: exhaled nitric oxide. LTRA: leukotriene receptor antagonist. Statistical significance was assumed for p < 0.050.